ABBV vs JNJ: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Johnson & Johnson · Healthcare
$238.46
-11.8% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
JNJ |
| Current Price |
$208.05 |
$238.46 |
| Fair Value Estimate |
$217.50 |
$210.28 |
| Upside to Fair Value |
+4.5%
|
-11.8%
|
| Market Cap |
$367.9B |
$574.7B |
| Forward P/E |
14.9x
|
20.2x
|
| EV / EBITDA |
16.7x
|
13.3x
|
| Price / Sales |
6.1x
|
6.2x
|
| Price / FCF |
20.9x
|
29.4x
|
| Revenue Growth YoY |
+8.6%
|
+6.1%
|
| Gross Margin |
83.7%
|
72.8%
|
| Operating Margin |
34.7%
|
27.2%
|
| Return on Equity |
-129.24%
|
32.87%
|
| Dividend Yield |
3.2% |
2.18% |
| FCF Yield |
4.78%
|
3.4%
|
| Analyst Consensus |
Buy
|
Moderate Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Johnson & Johnson is a high-quality healthcare conglomerate focused exclusively on Innovative Medicine and MedTech following the Kenvue spin-off. The company delivered $94.2B in FY2025 revenue with 6% operational growth, generated $19.7B in free cash flow, and guided for $99.5-100.5B in 2026 operational sales (above consensus). However, at $238 the stock trades at a P/S of 6.15x, well above the 5…
Accumulation Zones
| Metric |
ABBV |
JNJ |
| Zone Low |
$163.13 |
$157.71 |
| Zone High |
$184.88 |
$178.74 |
| In Buy Zone? |
No
|
No
|